ReviewMedicine2025
A review of proton beam therapy's role in glioma management.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment.Immunology and cell biology · 2026Review
- Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas pose significant therapeutic challenges due to limited survival and risks of treatment-related toxicity. Proton beam therapy (PBT) offers a precise radiation delivery method, minimizing damage to healthy brain tissue compared to conventional radiotherapy. This review synthesizes findings from 15 studies (2000-January 2024) from PubMed, Google Scholar, Science Direct, Cochrane Library, and Directory of Open Access Journals. PBT significantly reduces neurocognitive decline and enhances quality of life while achieving comparable or superior survival outcomes across various glioma types, including low-grade gliomas and glioblastomas. Notable benefits include improved verbal memory, stable intellectual functioning, and reduced high-grade toxicity. However, challenges such as neuroendocrine deficiencies and increased radiation necrosis highlight the need for optimized protocols. Future research should focus on comprehensive outcome assessments, proactive management of adverse effects, and improving PBT accessibility through cost reduction and technological advancements. PBT holds transformative potential in glioma management, balancing effective tumor control with preservation of neurological function, positioning it as a valuable neuro-oncology treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.